Skip to content
ORPHELIA Pharma
  • ORPHELIA Pharma
  • Therapeutic Areas
  • Products
  • Partners
  • Careers
  • News
  • Contact
×
  • ORPHELIA Pharma
  • Therapeutic Areas
  • Products
  • Partners
  • Careers
  • News
  • Contact

    Hear from us

    6 July 2022

    OCTALFA announces the inclusion of the first patient in the French Early Access Program granted to its subsidiary ORPHELIA Pharma for the use of KIMOZO® 40 mg/ml (temozolomide oral suspension) in the treatment of relapsed or refractory neuroblastoma

    Read More
    9 June 2022

    ORPHELIA Pharma and Gustave Roussy announce the publication in Pharmaceuticals of the scientific work related to the development of the first temozolomide oral suspension for children

    Read More
    31 May 2022

    ORPHELIA reports positive results of the bioequivalence study of KIMOZO® (oral suspension of temozolomide)

    Read More
    11 May 2022

    ORPHELIA Pharma has been awarded a € 1 million grant from Bpifrance to develop a therapy for a rare form of epilepsy

    Read More
    15 February 2022

    International Childhood Cancer Day

    Read More
    4 February 2022

    World Cancer Day

    Read More
    « Précédente1234567Suivant »

    ORPHELIA Pharma – 85 boulevard Saint Michel, 75005 Paris – France

    + 33 (0)1 42 77 08 18 – contact@orphelia-pharma.eu

    • Politique de confidentialité
    • Data privacy policy
    ×
    • Politique de confidentialité
    • Data privacy policy